Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 sepn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing
EX-99.1 2 sepn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif. – August 10, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the second quarter ended June 30, 2026. “We continue to make meaningful progress across our portfolio as we execute on our strategy to develop differentiated oral medicines targeting GPC...
Source
Exhibit EX-99.1
0001193125-26-342328
Filed August 10, 2026 at 8:03 PM UTC. The figures above are from the audited statements, not from this release.